Monitoring disease outcomes and side effects in patients with gastrointestinal cancers and sarcomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess disease outcomes and toxicities in patients with gastrointestinal malignancies and sarcomas receiving standard treatments, including radiotherapy. By utilizing standardized assessments, the study will prospectively monitor how recent advancements in treatment approaches impact patient outcomes and side effects. The findings will help refine current treatment strategies and inform future clinical trial designs.

Why it matters

Who can join: the full rules

Inclusion Criteria

In order to participate in this study a subject must meet all of the eligibility criteria outlined below.

1. Subject is willing and able to provide written informed consent to participate in the study and HIPAA authorization for the release of personal health information. Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designer.
2. Age ≥ 18 years at the time of consent.
3. Histological, cytological, or radiographic evidence/confirmation of a gastrointestinal malignancy or sarcoma.
4. Females with childbearing potential and male subjects with fathering potential are allowed to participate in this study.

Exclusion Criteria

All subjects meeting any exclusion criteria at baseline will be excluded from study participation.

1. Inability or unwillingness to provide informed consent
2. Patients who state they do not expect to be available or willing to follow up at expected intervals post-treatment

Where it's running

• University of North Carolina at Chapel Hill, Department of Radiation Oncology
  Chapel Hill, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Theodore K Yanagihara — Lineberger Comprehensive Cancer Center, The University of North Carolina Chapel Hill
• Study coordinator: Victoria Xu, MD, PhD
• Email: victoria_xu@med.unc.edu
• Phone: +1 984-974-8744

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing two radiation therapy techniques for advanced solid tumors

  This study is testing whether a new type of radiation therapy works better than the standard method for treating advanced solid tumors that have spread, to see if it can improve outcomes for patients needing palliative care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05837767

• Using blood tests to assess early treatment response in cancer patients

  This study is testing if blood tests that look for cancer DNA can help doctors see how well treatment is working for patients with different types of solid tumors.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT04354064

• Effects of Atezolizumab on Cancer Patients with Sensitive Tumor DNA or RNA

  This study is testing if atezolizumab can help cancer patients with certain tumor types that show they might respond well to the treatment.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT04273061

• Frailty before GI cancer surgery: does frailty predict post-op outcomes in older adults?

  This study tests whether frailty measured before surgery can predict complications and recovery in patients 60 and older undergoing elective gastrointestinal cancer surgery.

  Recruiting Van Training and Research Hospital · Van, Van · NCT07815392

• Biological Collection to Help Create Models for Digestive Cancers and IBD

  Researchers are gathering tissue and biological samples from patients with inflammatory bowel disease or digestive cancers to build personalized models and test new therapies.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07782203

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.